Swiss biotech Windward Bio Group files for U.S. IPO
Basel-based clinical-stage Windward Bio Group has filed for a Nasdaq IPO under ticker WWB, with share count and price range not yet disclosed.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing a regulatory filing, Windward Bio Group AG of Basel, Switzerland, intends to list its common stock on the Nasdaq Global Market under the symbol WWB. The company has not yet said how many shares it will offer or what price range it expects.
Founded in 2024, the developer has drawn up to $365 million in equity funding from backers such as RTW Investments, OrbiMed, SR One, Novo Holdings, Omega Funds and Blue Owl Healthcare Opportunities. Its ultra-long-acting antibodies target asthma, COPD and atopic dermatitis, and its headquarters is in Basel with operations in the US.
why it matters
For markets the signal is mainly about healthcare listings: a filing from a company backed by large specialist funds shows early-stage biotech is testing public markets again. Until the price range and share count appear, the size and valuation of the deal remain unknown.
tags
instruments
sources
- Windward Bio Group Files For U.S. IPO — TradingView, 24 October 2026 at 05:43 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗